Beauty Personal Care , Fragrance , Women's,Eau,loft-ministerstvo.ru,Women,Spray,Parfume,Tiffany,Co,2.5,/motophone785577.html,Intense,De,for,Ounces,,$101 Tiffany Co Intense for Women Eau Ounces De 2.5 Parfume Ranking TOP19 Spray $101 Tiffany Co Intense for Women Eau De Parfume Spray 2.5 Ounces, Beauty Personal Care Fragrance Women's Beauty Personal Care , Fragrance , Women's,Eau,loft-ministerstvo.ru,Women,Spray,Parfume,Tiffany,Co,2.5,/motophone785577.html,Intense,De,for,Ounces,,$101 $101 Tiffany Co Intense for Women Eau De Parfume Spray 2.5 Ounces, Beauty Personal Care Fragrance Women's Tiffany Co Intense for Women Eau Ounces De 2.5 Parfume Ranking TOP19 Spray

Tiffany Co Intense for Women Eau Ounces De 2.5 Parfume Ranking Online limited product TOP19 Spray

Tiffany Co Intense for Women Eau De Parfume Spray 2.5 Ounces,

$101

Tiffany Co Intense for Women Eau De Parfume Spray 2.5 Ounces,

|||

Product description

What it is: An intense, richer and deeper version of the signature artisanal fragrance.

Fragrance story: Tiffany Eau de Parfum Intense is a powerful musky and floral interpretation of the original wrapped in warm, sensual accord that takes the juice a step further. The key note, a richer concentration of iris butter echoes its predecessor with a deep intensity that adds extraordinary depth. The drydown strengthens in opulence through luxurious raw materials of amber benzoin. Once again, world renowned master perfumer Daniela Andrier created this scent inspired by optimism, strength and joy, a pure essence of the Tiffany brand. At Tiffany, all you need is love. Presented in a stunning, faceted glass flacon, it takes its inspiration from the house's most iconic diamond cuts. The new rendition is illuminated with a deeper shade of the iconic Tiffany Blue and offset by a brilliant silver collar embossed with the Tiffany amp; Co. logo.

Tiffany Co Intense for Women Eau De Parfume Spray 2.5 Ounces,

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA